Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Receivables - Net for 14 consecutive years, with $218.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 8634.16% year-over-year to $218.4 million, compared with a TTM value of $218.4 million through Dec 2025, up 8634.16%, and an annual FY2025 reading of $6.8 million, changed N/A over the prior year.
  • Receivables - Net was $218.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $6.8 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $218.4 million in Q4 2025 and bottomed at $150000.0 in Q4 2021.
  • Average Receivables - Net over 5 years is $24.4 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Receivables - Net tumbled 98.33% in 2021, then skyrocketed 26278.67% in 2022.
  • Year by year, Receivables - Net stood at $150000.0 in 2021, then surged by 26278.67% to $39.6 million in 2022, then plummeted by 96.85% to $1.2 million in 2023, then skyrocketed by 100.48% to $2.5 million in 2024, then soared by 8634.16% to $218.4 million in 2025.
  • Business Quant data shows Receivables - Net for ARWR at $218.4 million in Q4 2025, $6.8 million in Q3 2025, and $9.7 million in Q2 2025.